Login to Your Account

Vertex Targets Kalydeco as Incivek Sales Continue Swoon

By Marie Powers
Staff Writer

Thursday, January 31, 2013
After Tuesday's market close, Vertex Pharmaceuticals Inc. reported 2012 revenues of $1.53 billion, including net product revenues of $1.16 billion from Incivek (telaprevir) and $171.6 million from Kalydeco (ivacaftor), launched in the U.S. in February 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription